The Impact of Bisphenol A on Thyroid Function in Neonates and Children: A Systematic Review of the Literature

Diamanto Koutaki 1,†, George Paltoglou 1,†, Aikaterini Vourdoumpa 1 and Evangelia Charmandari 1,2, *

1 Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, 11527 Athens, Greece; dkoutaki@med.uoa.gr (D.K.); gpalto@gmail.com (G.P.); katvourdouba@gmail.com (A.V.)
2 Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece
* Correspondence: evangelia.charmandari@gmail.com; Tel./Fax: +30-213-2013-384
† These authors contributed equally to this work.

Abstract: Background: Bisphenol A (BPA) is an endocrine-disrupting chemical widely used in plastic products that may have an adverse effect on several physiologic functions in children. The aim of this systematic review is to summarize the current knowledge of the impact of BPA concentrations on thyroid function in neonates, children, and adolescents. Methods: A systematic search of Medline, Scopus, Clinical Trials.gov, Cochrane Central Register of Controlled Trials CENTRAL, and Google Scholar databases according to PRISMA guidelines was performed. Only case–control, cross-sectional, and cohort studies that assessed the relationship between Bisphenol A and thyroid function in neonates and children aged <18 years were included. Initially, 102 articles were assessed, which were restricted to 73 articles after exclusion of duplicates. A total of 73 articles were assessed by two independent researchers based on the title/abstract and the predetermined inclusion and exclusion criteria. According to the eligibility criteria, 18 full-text articles were selected for further assessment. Finally, 12 full-text articles were included in the present systematic review. Results: The presented studies offer data that suggest a negative correlation of BPA concentrations with TSH in children, a gender-specific manner of action, and a potential effect on proper neurodevelopment. However, the results are inconclusive with respect to specific thyroid hormone concentrations and the effect on thyroid autoimmunity. Conclusion: The potential negative effect of BPA in the developing thyroid gland of children that may affect proper neurodevelopment, suggesting the need to focus future research on designing studies that elucidate the underlying mechanisms and the effects of BPA in thyroid function in early life.

Keywords: bisphenol; BPA; thyroid; children; neonates; TSH; T4; neurodevelopment

1. Introduction

In recent decades, accumulating evidence has demonstrated the impact of environmental endocrine-disrupting chemicals (EDCs) on human health [1]. These substances are defined by the U.S. Environmental Protection Agency (EPA) as “an exogenous agent that interferes with synthesis, secretion, transport, metabolism, binding action, or elimination of natural blood-borne hormones that are present in the body and are responsible for homeostasis, reproduction, and developmental process” [1]. This definition is further detailed by the World Health Organization as “an exogenous substance or mixture that alters the function(s) of the endocrine system and consequently causes adverse effects in an intact organism, or its progeny, or (sub) populations” [2]. Endocrine-disrupting chemicals are a heterogeneous group and can be detected in a wide spectrum of daily used products. Bisphenol A (BPA, 4,4′-isopropylidenediphenol) is a monomer EDC used in the manufacture of poly-carbonate plastics and epoxy resins [3]. It is also highly used in consumer products, such as baby feeding bottles, protective coatings inside food containers, and water
supply pipes, as an additive that can improve the properties of plastics [4,5]. The exposure is ubiquitous given that BPA is one of the chemical compounds used in massive amounts in the production of synthetic polymers and thermal paper, with an annual production of at least 8 million tons throughout the world, while the European Union has legally restricted the use of BPA in thermal paper in concentration equal to or greater than 0.02% by weight [5,6]. Oral use is considered to be the primary route of contamination, followed by the dermal route; however, there are also reports suggesting the possibility of indoor air contamination [7]. In addition to adults, children are also highly exposed to it as well [8]. In a large study of 2517 participants conducted by the Centers for Disease Control, children had significantly higher concentrations of BPA compared with adults, which, along with the reported presence of BPA in amniotic fluid, suggest an early exposure affecting almost every organ, including the function of the reproductive and the cardiovascular system, the cognitive and behavioral development, and the pathogenesis of obesity [11–13]. Moreover, animal and human studies provide evidence of this particular phenol interfering with the pituitary–thyroid axis [14]. Mechanistically, BPA acts on various molecular pathways in many tissues. It can interact with numerous receptors, including nuclear and membrane-bound receptors, as well as transcription factors, and it may also induce epigenetic changes [15–17]. The more thoroughly described interaction of BPA is that with nuclear steroid estrogen receptors alpha (ERα) and beta (ERβ) [18]. Bisphenol A also binds with a strong affinity to estrogen-related receptors gamma (ERRγ) [19]. After binding with the receptor, BPA can act like an estrogen, albeit with a weaker activity than 17-beta estradiol (E2) [20]. Moreover, its estrogenic properties are influenced by the ratio of estrogen receptor (ER) subtypes in a particular cell/tissue, suggesting differential responsiveness [18]. BPA also displays anti-androgenic properties, being a competitive antagonist to 5α-dihydrotestosterone (DHT) for binding to the androgen receptor (AR) [21,22]. Of note, some studies have indicated that BPA can act as an agonist of the glucocorticoid receptor (GR) [23,24].

Accumulating evidence suggests a role of BPA in transcription factor physiology. Firstly, BPA can induce peroxisome proliferator-activated receptor γ (PPARγ) and thus adipogenesis in several (animal) models [25]. The expression of genes essential for proper growth and development, such as HOXC1 and HOXC6, WNT5A, FZD5, TGFβ2, and SOCS2, is also affected by this BPA [26]. Furthermore, it can cause epigenetic changes, such as altered methylation and interpretation with the expression of multiple microRNAs (miRNAs) [27–29].

Bisphenol A can perturb normal thyroid function in many ways, including interaction of cellular signaling and gene expression (transcription) [30]. The majority of in vitro studies suggest that BPA binds to thyroid hormone receptors (TR)-alpha and TR-beta, thereby antagonizing the action of triiodothyronine (T3) and suppressing its transcriptional activity [30–33]. Some studies indicated that BPA can act as an agonist to the thyroid receptor, especially in very low doses, that could potentially suggest a non-monotonic dose response (NMDR) that could go against predictable or typical dose–response patterns [34,35]. Furthermore, a low dose of BPA suppresses T3-induced transcription by recruiting nuclear receptor co-repressors (N-CoRs) to the thyroid receptor [30]. The recruitment of N-CoR to TR-beta1 by BPA in a low-dose exposure is mediated through a non-genomic mechanism by β3 integrin/c-Src/MAPK/TR-beta1 pathways [36]. When BPA is detected in usual concentrations in human serum, there is no significant competition for binding with thyroid hormone transport proteins (human serum albumin (HSA), transthyretin (TTR), and thyroxine-binding globulin (TBG)) despite its structural similarity to thyroxine (T4) and T3 [37]. At the gene level, BPA can interact with the expression of numerous genes affecting thyroid homeostasis, including genes associated with inhibition of different types of deiodinases [38,39]. Moreover, it disrupts the expression of genes involved in thyroid hormones synthesis (tshβ, Slc5a5, Tpo, and Tgo, Pax8, Foxe1, and Nkx2-1) through a direct effect on thyroid follicular cells but not on the activity of thyroid peroxidase [39–41].
it inhibits sodium/iodide symporter (NIS)-mediated iodide uptake at the post-translational level [39].

Results from a cross-sectional study on a human cohort from the National Health and Nutrition Examination Survey (NHANES) study in 1346 adults indicated an inverse relationship between urinary BPA and total thyroxine and thyroid-stimulating hormone (TSH) [42]. This is particularly worrying given the fact that normal thyroid function is important for the developing brain of the fetus [43]. It should be noted that these substances can cross the placenta and affect the developing fetus [44]. In addition, there is evidence that even mild maternal hypothyroxinemia during gestation can alter fetal neurodevelopment, behavior, and cognition in the offspring [43,45,46]. Apart from short-term health risks, it still remains unclear whether this substance can affect the thyroid function later in life, given the hypothesis of the developmental origins of health and disease (DOHaD) [47]. Although BPA may have long-term adverse effects on several functions and may lead to trans-generational changes in children’s behavior, it is not clear whether it affects thyroid function [48,49].

Epidemiological studies reveal a possible effect of BPA on thyroid function in adult populations; however, few data exist regarding its effect in children and adolescents. The aim of this systematic review is to summarize the current knowledge on adverse effects of BPA on the pituitary–thyroid axis of neonates, children, and adolescents.

2. Materials and Methods

2.1. Study Design

The present study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol (supplementary material) [50]. The study protocol included the following consecutive stages: (i) primary research of the systematic literature using search engines; (ii) selection of studies to be included according to our inclusion and exclusion criteria; (iii) data extraction; and (iv) data synthesis and analysis.

2.2. Eligibility Criteria

The eligibility criteria were predetermined by the authors. In order to prevent language bias, our search was not limited by language. Additionally, there was no date or country restriction. We included case–control, cross-sectional, and cohort studies that assessed the relationship between BPA and thyroid function in neonates and children younger than 18 years. Reviews, letters, abstracts, case reports, expert opinions, and in vitro or animal experiments were excluded from our data selection. All inclusion and exclusion criteria in terms of study type, participants, language, geographic location, and outcomes are described in Table 1.

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| Age < 18 years     | Age ≥ 18 years     |
| Studies from any geographic location | Reviews, editorials, abstracts, case–controls, expert opinions |
| Any publication date | In vitro or animal experiments |
| Observational and interventional studies |                    |
| Any language       |                    |
| Assessing the relationship between BPA (maternal or neonatal) and thyroid function in neonates, children, and adolescents |                    |

2.3. Literature Search

Two independent reviewers (DK) and (GP) used the Medline (2005–2021), Scopus (2005–2020), Clinical Trials.gov (2008–2021), Cochrane Central Register of Controlled Trials
CENTRAL (2011–2021), and Google Scholar (2005–2021) search engines in primary search prior to June 2021.

Our search strategy included the terms: “thyroid*” [All Fields] AND (“bisphenol*” [All Fields] OR “bisphenol a” [All Fields] OR “BPA” [All Fields]) AND (“child*” [All Fields] OR “adolescent*” [All Fields] OR “neonat*” [All Fields]). Articles together with reference lists from included studies were retrieved.

2.4. Study Selection

After the initial search, all the obtained documents were screened independently by the two reviewers (DK and GP). The two reviewers used Mendeley software to exclude all duplicates and examined eligibility for the studies based on the relevance of their title and abstract to the subject (first eligibility check). For the relevant articles, full text was assessed based on the inclusion and exclusion criteria (second eligibility check). During the whole procedure, each reviewer remained blinded to the other investigator’s selection. When conflict between the two authors occurred, it was resolved through a third author (AV).

Following the terms listed above, the electronic database search resulted in 102 articles, which were then checked for duplicates. After exclusion of duplicates, our list was restricted to 73 articles. No additional records were from other sources (manual research, reference lists of other papers). A total of 73 articles were thoroughly assessed by two independent researchers based on title/abstract and the inclusion and exclusion criteria. According to the eligibility criteria, 18 full-text articles remained for further assessment. Among these full-text articles, 6 were excluded for the following reasons: wrong study type, namely reviews/systematic reviews, or information that did not meet the eligibility criteria and the purpose of this systematic review (third step). Finally, 12 full-text articles were considered eligible and were included in our qualitative synthesis. The study selection procedure is detailed in the respective flow chart (Figure 1).

![Flow chart](image)

**Figure 1.** Flow chart describing the step-wise selection (identification, screening, eligibility, inclusion) of the studies included in the qualitative synthesis.
2.5. Data Extraction

Data extraction was conducted using a standardized excel data extraction form, and the process was regulated by the same two reviewers (DK and GP), who worked blinded and separately. The following data items were extracted: reference of the article (Author, Year), study type (case-controls, case series, cohort studies, randomized controlled trials), sample characteristics and concentrations of BPA and thyroid hormones, and time and method of BPA measurement.

3. Results

In 2013, the Center for the Health Assessment of Mothers and Children of Salinas study (CHAMACOS) investigated in a Mexican-American population the impact of maternal BPA exposure during the first and second half of pregnancy on offspring’s TSH [51]. The researchers revealed a statistically significant ($p = 0.01$) inverse relationship in male neonates ($-9.9\%$ per log2 unit; $95\%$ CI: $-15.9\%$, $-3.5\%$) but not in females ($4.4\%$ for every doubling in average BPA; $95\%$ CI: $-2.4\%$, 11.7). Furthermore, among boys, the association was stronger when maternal BPA urinary concentrations were measured in the third trimester of gestation, suggesting a developmental window of susceptibility. Moreover, in the Health Outcomes and Measures of the Environment (HOME) Study, a 10-fold increase in mean BPA was associated with lower cord TSH concentrations in girls (percent change = $-36.0\%$; 95% CI: $-58.4\%$, $-1.7\%$) [52]. Similar to the CHAMACOS study, a more evident effect of BPA was observed during late gestation. A suggestive positive association between maternal urinary BPA and TT3 concentrations among newborn females was also observed ($p = 0.11$). The inverse BPA–TSH relation among girls was stronger but less precise among iodine deficient mothers. A negative correlation between BPA concentrations and TSH ($r = -0.25$, $p = 0.077$) was observed in another small cohort of 53 newborn males similar to previous studies [53].

Fen Li et al. evaluated the effect of the exposure to BPA during the first trimester of gestation on children’s neurobehavioral development at 2 years and 4 years. A significant inverse relationship between BPA and TSH concentrations in both boys and girls was noted ($\beta_{\text{highest}} = -1.91$, 95%CI: $-3.32$, $-0.50$; for boys, $\beta_{\text{highest}} = -1.89$, 95%CI: $-3.70$, $-0.50$; for girls, $\beta_{\text{middle}} = -2.34$, 95%CI: $-4.61$, $-0.07$). Children with the middle or highest tertile of BPA concentration also had lower TT3 ($\beta_{\text{highest}} = -0.05$, 95%CI: $-0.10$, $-0.01$), FT3 ($\beta_{\text{highest}} = -0.12$, 95%CI: $-0.22$, $-0.02$; $\beta_{\text{middle}} = -0.11$, 95%CI: $-0.21$, $-0.01$). Therefore, it was suggested that prenatal BPA exposure may be associated with increased risk of neurobehavioral problems, especially in boys [54].

The same strategy was followed in a longitudinal cohort of Asian population, where maternal urinary BPA concentrations were associated with increased risk of total difficulties in children aged 10 years in a gender-specific manner, with boys being more vulnerable. Concerning the thyroid hormones, BPA levels were significantly correlated with 1.00% (95%CI: 0.20%, 1.92%) increases in cord serum FT4 concentrations [55].

However, some studies reported no association between BPA and thyroid hormone levels, such as the Hokaido study (Pinteraction = 0.819 for TSH and P interaction = 0.969 for FT4) [56], and a cross-sectional study in which pregnant women were stratified according to BMI (BMI < 18.5, 18.5–22.9 or ≥23 kg/m$^2$) [57]. No association was observed between prenatal urinary BPA concentration and cord serum FT4, FT3, TSH concentrations of neonates, as well as the odds of TPO-Ab positivity (>5.61 IU/mL). However, in mothers with higher BMI and higher BPA exposure, cord serum FT4 was 2.96 (95% CI 0.12–5.80) pmol/L higher in male newborns and 2.22 (95% CI 0.67–3.78) pmol/L higher in female newborns compared to those in the low tertile of BPA levels. No significant association was detected between cord blood concentrations of T4, TSH, SPINA-GT (thyroid incretory capacity), TSH Index (TSHI), standardized TSHI (sTSHI) concentrations of infants, and cord blood BPA in both genders included in another report [58]. Finally, in a recent publication, BPA was measured twice (during gestation and at 6 years); however, there was not any
significant association except a relationship between prenatal BPA and T3 only when stratified by sex [59].

Only one study reports a positive association between BPA and TSH [60]. In this cohort, urine samples for detection of the xenobiotic were acquired during early, middle, and late pregnancy (<18, 18–25, >25 weeks gestational age) and thyroid function was evaluated both short-term after birth and long-term in childhood (5.9 years). A higher BPA level during late pregnancy was associated with a higher cord blood TSH in newborns, especially in females, but not in early or mid-pregnancy (β (95% CI): 0.04 (0.007 to 0.07)) and a lower FT4 concentration in childhood (β (95% CI): −0.11 (−0.21 to −0.01)).

Limited data exist concerning the effects of BPA on thyroid volume, the presence of thyroid nodules and Hashimoto thyroiditis. Urinary BPA concentration was negatively associated with thyroid volume (assessed by thyroid ultrasonography) in 718 children aged 9–11 years (β = −0.033, 95% CI: −0.053, −0.013) and the risk for multiple nodules but not with the risk of solitary nodules (n = 100, OR = 0.78; 95% CI: 0.63, 0.97) [61]. Specifically, each log unit increase in BPA level was associated with a 0.088 SD unit decrease in thyroid volume. The median thyroid volume of participants was 3.14 mL and was similar for boys (3.05 mL) and girls (3.21 mL). The authors attributed this decrease in thyroid volume to a possible negative correlation between BPA and TSH.

Sur et al. examined the relationship between BPA and Hashimoto thyroiditis (HT) (diagnosis was made by i. increased plasma concentrations of thyroid peroxidase auto-antibodies (anti-TPO); ii. heterogeneous echo-texture in thyroidal ultrasound) [62]. Urinary BPA levels were not significantly different in the HT group and the control group. There was a negative correlation between BPA level and FT4 concentrations (r = −0.483, p < 0.02), and no correlation was observed between urinary BPA concentrations and anti-TPO levels (p = 0.063).

The details of the included studies are presented in Tables 2–4. More specifically, the characteristics of each study concerning the design, number of participants, sample of thyroid hormones, BPA sample, and time of BPA measurement are presented in Table 2. Mean/median values for each study of BPA and thyroid hormones (TSH, FT4, TT4, FT3, TT3) are presented in Table 3. The statistically significant odds ratios (OR), correlations (r), or logistic regression models (betas) of the association of BPA with TSH, T4 and T3 where applicable are presented in Table 4.
Table 2. General characteristics of included studies.

| Authors                     | Number of Children | Method of BPA Measurement                                                                 | BPA Sample          | TSH Sample      | Study Characteristics         | Time of BPA Measurement                  |
|-----------------------------|--------------------|-------------------------------------------------------------------------------------------|---------------------|----------------|---------------------------|------------------------------------------|
| Brucker-Davis et al. (2011) [53] | 53 (only boys)    | Chromatography coupled with mass spectrometry                                              | Cord blood          | Cord blood      | Prospective–Cohort        | At birth                                 |
| Chevrier et al. (2013) [51]  | 364                | Online solid-phase extraction coupled with isotope dilution–high-performance liquid chromatography–negative ion–atmospheric pressure chemical ionization tandem mass spectrometry | Urine               | Blood spots     | Cohort                    | 12.4 ± 3.8 and 26.2 ± 2.2 weeks of gestation |
| Romano et al. (2015) [52]   | 249                | Online solid-phase extraction coupled to high-performance liquid chromatography-isotope dilution tandem mass spectrometry | Urine               | Cord blood      | Prospective               | 16 (13.0–20.9) and 26 (23.1–34.6) weeks of gestation |
| Wang et al. (2015) [61]     | 718                | Ultra-performance liquid chromatography coupled with tandem mass spectrometry               | Urine               |                | Cross-sectional           | 9–11 years old                           |
| Minatoya et al. (2017) [56] | 283                | Isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC/MS/MS)              | Cord blood          | Heel-prick blood sample | Prospective–Cohort | At birth                                 |
| Sanlidag et al. (2018) [58] | 88                 | Sandwich enzyme—linked Immunosorbent assays (ELISAs)                                      | Cord blood          | Cord blood      | Cross-sectional           | At birth                                 |
| Sur et al. (2019) [62]      | 29 and 29 control group | High-pressure liquid chromatography (HPLC)                                               | Urine               |                | Case-control              | 8–16 years old                           |
| Wang et al. (2020) [57]     | 398                | Liquid chromatography tandem mass spectrometry (HPLC-MS/MS)                               | Urine               | Cord blood      | Cohort                    | Late pregnancy (38.8 ± 1.1 weeks of gestation) |
| Fen Li et al. (2020) [54]   | 348                | High-performance liquid chromatography (HPLC)                                             | Urine               | Cord blood      | Prospective               | 12–16 weeks of gestation                 |
| Guo et al. (2020) [55]      | 386                | Gas chromatography tandem mass spectrometry                                               | Urine               | Cord blood      | Prospective–Cohort        | At birth                                 |
| Derakhshan et al. (2020) [60] | 853 neonates   | Liquid–liquid extraction (LLE) followed by enzymatic deconjugation of the glucuronidated bisphenols accompanied by high performance liquid chromatography electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS/MS) | Urine               | Cord blood      | Prospective               | <18, 18–25, >25 weeks of gestation        |
|                            | 882 children       |                                                                                           |                     |                |                           |                                         |
| Jang et al., 2021 [59]      | 574                | High-performance liquid chromatography-tandem mass spectrometry                           | Urine               | Blood sample   | Prospective–Cohort        | 20 weeks of gestation and 6 years old children |

Abbreviations: TSH: thyroid-stimulating hormone; BPA: bisphenol A.

Table 3. Mean concentrations of BPA and thyroid hormones.

| Authors                     | TSH Mean: 7.67 mIU/L (SD: 5.04) | T4 Mean: FT4 = 13.04 pmol/L (SD: 1.54) | Other Median: 0.9 ng/mL (Range: 0.2–3.3) |
|-----------------------------|---------------------------------|----------------------------------------|------------------------------------------|
| Brucker-Davis et al. (2011) [53] | | | |
Table 3. Cont.

| Authors                  | TSH T3 T4 BPA Other |
|--------------------------|---------------------|-------------------|
| Chevrier et al. (2013)   | GM: 5.6 mIU/L (GSD:1.8) ↓ (boys) Mean ± SD FT3 = 1.7 ± 0.3 pg/mL. TT3 = 52 ± 19 ng/dL ↑ Mean ± SD FT4 = 1.0 ± 0.2 ng/dL TT4 = 9.6 ± 1.8 mg/dL (-) | Median: 1.2 mg/g creatinine (IQR: 0.8–1.9) |
| Romano et al. (2015)     | Mean: 7.2 mIU/L (95% CI: 6.7, 7.8) ↓ (girls) Median: 1.2 pg/g Cr (IQR: 0.8–1.9) | Median BPA (mg/g Cr) = 2.2 (IQR:1.5–3.4) |
| Wang et al. (2015)       | Mean: 7.2 mIU/L (95% CI: 6.7, 7.8) ↓ (girls) Mean ± SD FT3 = 1.7 ± 0.3 pg/mL TT3 = 52 ± 19 ng/dL ↑ Mean ± SD FT4 = 1.0 ± 0.2 ng/dL TT4 = 9.6 ± 1.8 mg/dL (-) | Median: 2.45 (IQR: 1.09–5.97) µg/g creatinine Median thyroid volume: 3.14 mL (IQR: 2.44–4.11) |
| Minatoya et al. (2017)   | Mean: 7.2 mIU/L (95% CI: 6.7, 7.8) ↓ (girls) Mean ± SD FT3 = 1.7 ± 0.3 pg/mL TT3 = 52 ± 19 ng/dL ↑ Mean ± SD FT4 = 1.0 ± 0.2 ng/dL TT4 = 9.6 ± 1.8 mg/dL (-) | Mean ± SD: 0.057 ± 0.036 ng/mL |
| Wang et al. (2020)       | Mean: 7.2 mIU/L (95% CI: 6.7, 7.8) ↓ (girls) Mean ± SD FT3 = 1.7 ± 0.3 pg/mL TT3 = 52 ± 19 ng/dL ↑ Mean ± SD FT4 = 1.0 ± 0.2 ng/dL TT4 = 9.6 ± 1.8 mg/dL (-) | Median: 2.45 (IQR: 1.09–5.97) µg/g creatinine Median thyroid volume: 3.14 mL (IQR: 2.44–4.11) |
| Sanlidag et al. (2018)   | Mean ± SD: 4.9 ± 1.7 µIU/mL ↓ (boys) Mean ± SD: FT4 = 0.95 ± 0.2 ng/dL ↑ Mean ± SD: 4.93 ± 2.33 ng/mL (−) | Mean ± SEM: 7.72 ± 1.74 in control group and Mean ± SEM: 7.31 ± 1.46 in HT group (µg/g creatinine) (−) |
| Sur et al. (2019)        | Mean ± SD: 4.85 ± 1.73 µIU/mL ↓ (boys) Mean ± SD: FT4 = 0.95 ± 0.2 ng/dL ↑ Mean ± SD: 4.93 ± 2.33 ng/mL (−) | Positivity of TPO-Ab Mean ± SD: Low tertile: 11 (8.3) Medium tertile: 15 (11.4) High tertile: 8 (5.9) (−) |
| Fen Li et al. (2020)     | Median: 6.43 µIU/L ↓ Mean ± SD: FT3 = 0.85 pmol/L Mean ± SD: FT4 = 14.18 pmol/L Mean ± SD: 4.93 ± 2.33 ng/mL (−) | Mean ± SEM: 7.72 ± 1.74 in control group and Mean ± SEM: 7.31 ± 1.46 in HT group (µg/g creatinine) (−) |
| Guo et al. (2020)        | Median: 6.88 pmol/L (IQR: 4.93–9.49) ↓ Mean ± SD: FT3 = 2.5 (IQR: 2.3–2.7) pmol/L Mean ± SD: FT4 = 16.0 (IQR: 14.8–17.2) pmol/L Mean ± SD: 4.93 ± 2.33 ng/mL (−) | Mean ± SEM: 7.72 ± 1.74 in control group and Mean ± SEM: 7.31 ± 1.46 in HT group (µg/g creatinine) (−) |
| Derakhshan et al. (2020) | Median (95% range) Newborn: 9.57 µIU/L (3.13–34.7) Child: 2.33 µIU/L (0.92–4.87) Mean ± SD: FT3 = 1.78 pmol/L Mean ± SD: FT4 = 14.18 pmol/L Mean ± SD: 4.93 ± 2.33 ng/mL (−) | Mean ± SEM: 7.72 ± 1.74 in control group and Mean ± SEM: 7.31 ± 1.46 in HT group (µg/g creatinine) (−) |
| Jang et al. (2021)       | Mean ± SD: 2.55 ± 1.36 µIU/mL ↓ Mean ± SD: FT3 = 148.00 ± 18.47 ng/dL ↑ Mean ± SD: FT4 = 1.15 ± 0.11 ng/dL ↑ Mean ± SD: 2.73 ± 7.15 µg/L Mean ± SD: Prenatal: 2.15 ± 2.85 µg/g Cr | Mean ± SEM: 7.72 ± 1.74 in control group and Mean ± SEM: 7.31 ± 1.46 in HT group (µg/g creatinine) (−) |

Abbreviations: TSH: thyroid-stimulating hormone; BPA: bisphenol A; T4: thyroxine (T4); T3: Triiodothyronine; SD: Standard deviation; IQR: Interquartile Range; GM: Geometric Mean, GSD: Geometric Standard Deviation, SEM: Standard Error of the mean, CI: Confidence Interval, LOD: Limit of detection. ↓: negative association, ↑: positive association, (−) no significant association.
Table 4. Statistically significant correlations (r), odds ratios (OR), or logistic regression models (betas) of the association of BPA with TSH, T4, and T3.

| TSH                        | Details                                                                                     |
|---------------------------|---------------------------------------------------------------------------------------------|
| Brucker-Davis et al. (2011) [53] | Negative correlation between BPA concentrations and TSH (r = −0.25, p = 0.077)             |
| Chevrier et al. (2013) [51]  | Inverse relationship between maternal BPA concentrations and TSH in boys (- 9.9% per log2 unit; 95% CI: −15.9% to −3.5%) |
| Romano et al. (2015) [52]   | Inverse relationship between maternal BPA concentrations and TSH in girls (percent change = −36.0%; 95% CI: −58.4% to −1.7%) |
| Fen Li et al. (2020) [54]   | Significant inverse relationship between BPA and TSH concentrations Overall: (β highest = −1.91, 95% CI: −3.32 to −0.50); for boys: (β highest = −1.89, 95% CI: −3.70 to −0.50) and for girls: (β middle = −2.34, 95% CI: −4.61 to −0.07) |
| Derakhshan et al. (2020) [60] | Positive association of BPA with TSH in newborns, especially in females [β 95% CI: 0.04 (0.007)] |

| T4                         | Details                                                                                     |
|---------------------------|---------------------------------------------------------------------------------------------|
| Sur et al. (2019) [62]     | Negative correlation between BPA level and FT4 concentrations (r = −0.483, p < 0.02)          |
| Wang et al. (2020) [57]     | In mothers with higher BMI and higher BPA exposure, cord serum FT4 was 2.96 (95% CI: 0.12−5.80) pmol/L higher in male newborns and 2.22 (95% CI: 0.67−3.78) pmol/L higher in female newborns compared to those in the low tertile of BPA levels. |
| Guo et al. (2020) [55]      | Maternal BPA concentrations were positively correlated with 1.00% (95% CI: 0.20%, 1.92%) increases in cord serum FT4 concentrations |
| Derakhshan et al. (2020) [60] | Lower FT4 concentration in childhood (β 95% CI: −0.11 (−0.21 to −0.01))                      |

| T3                         | Details                                                                                     |
|---------------------------|---------------------------------------------------------------------------------------------|
| Fen Li et al. (2020) [54]  | Children with the middle or highest tertile of BPA concentration also had lower TT3 (β highest = −0.05, 95% CI: −0.10 to −0.01), FT3 (β highest = −0.12, 95% CI: −0.22 to −0.02; β middle = −0.11, 95% CI: −0.21 to −0.01). |
| Jang et al., 2021 [59]     | Gender specific effect between prenatal BPA and T3 concentrations (Boys p = 0.025; Girls p = 0.028) |

Thyroid volume and multiple nodules risk

| Wang et al. (2015) [61]     | Inverse association between urinary BPA concentration and thyroid volume (β = −0.033, 95% CI: −0.053 to −0.013) |
|                            | Negative association with the risk of multiple nodules (OR = 0.78; 95% CI: 0.63 to 0.97) |

Abbreviations: TSH: thyroid stimulating hormone; BPA: bisphenol A; T4: thyroxine (T4); T3: Triiodothyronine; OR: Odds Ratio; CI: Confidence Interval.
4. Discussion

Bisphenol A (BPA) preserves endocrine disruptive properties and can interact with almost every human system. Humans are ubiquitously exposed daily to plastic products in the modern world [63]. An expanding number of studies address the impact of BPA in thyroid function in recent years [14,64]. Many researchers have tried to evaluate the trace of xenobiotic exposure, such as BPA, on thyroid function and specifically in the pediatric population.

We found that many of the collected data in children suggest a negative correlation of BPA levels with TSH; however, the results are inconclusive with respect to the thyroid hormone concentrations. Similarly, in large adult studies, BPA was associated inversely with TSH concentrations [42,65,66]. This observation can be attributed to the structural similarity of BPA to the thyroid hormones, thyroxine (T4), and triiodothyronine (T3), and its action as an antagonist or agonist of the thyroid receptor [34,35]. Experimental data indicated that BPA could suppress the TRH-induced release of both TSH and prolactin [67]. The suppression of TSH secretion from the pituitary was independent of the thyroid hormone negative feedback and the estrogenic activity of BPA [67]. Moreover, this association is in accordance with the reported decrease in thyroid volume [61]. An exposure to high concentrations of BPA may result in lower concentrations of TSH and consequently to a decreased volume of the thyroid gland [61]. It is well described that TSH stimulates hypertrophy and hyperplasia of the thyroid follicular cells, leading to the enlargement of the thyroid, while TSH also increases blood flow to the thyroid gland [68]. Although embryogenesis of the thyroid is reported to be independent of TSH until the 14th week of gestation [69], it can be hypothesized that lower concentrations of fetal TSH during late gestation would lead to decreased volume of thyroid gland given the loss of TSH trophic effect, it has been reported in autopsy findings in patients with congenital hypopituitarism [70].

Several studies support the concept that BPA can act in a gender-specific manner [51,52] because of its ability to interact with estrogen and androgen receptors [16]. This differential responsiveness of BPA can be shown when assessing its estrogenic properties and how they are influenced by the ratio of ER subtypes in a particular cell/tissue [18]. Rodent studies have also assessed a gender-specific effect of BPA with contradicting results [71,72]. While one experimental study found that exposure to BPA during pregnancy and postpartum was related to alterations in FT4 among male rodents in a dose-dependent manner [72], another showed similar thyroid hormone responses to BPA in both male and female rodents [71]. A gender-specific impact of BPA apart was also observed on fetal organ weights, steroid profiles, and growth trajectories [73]. Furthermore, several studies evaluated the effect of BPA on the thyroid function of neonates, given that thyroid hormones are essential for proper brain development during early life stages and that BPA can cross the placenta [74,75]. In addition, in utero exposure can result in toxicity as fetuses lack the enzyme UDP-glucuronosyltransferase (UDPGT) required to metabolize BPA and thus are more sensitive [76]. The possibility of a vulnerable time window during perinatal exposure and offspring’s thyroid function has also been assessed as it has been shown that exposure at late gestation prior to birth can have more evident effects on thyroid function [51,52]. This result is in line with thyroid gland organogenesis, as fetal thyroid gland becomes mature and begins to produce thyroid hormones after week 20 of gestation; therefore, BPA exposure after the second trimester of pregnancy could have a greater effect on fetal thyroid gland function [77]. However, this differential effect of BPA on thyroid function after the second trimester can be confounded by the potentially shorter period between the measurement of BPA and thyroid hormones at birth.

Accumulating evidence suggests that the increased prevalence of autoimmunity in industrial areas may be attributed only to the exposure to “endocrine disrupting chemicals” [78]. BPA has been linked to the pathophysiology of autoimmune diseases [79]. Perinatal exposure to BPA predisposes mouse pups to the development of asthma [80]. Autoimmune hypothyroidism in childhood has an estimated prevalence of 1% to 2% and is characterized by gender dimorphism with a 4:1 female predominance [81]. When thy-
roid autoimmunity was assessed in children and adolescents, no significant correlation of anti-TPO antibodies and heterogeneous echo-texture in thyroidal ultrasound with BPA was found [57,62]. However, another study conducted in 2361 adults, aged >15 years, found that BPA was independently associated with positive anti-TPO antibodies [82]. A variety of mechanisms by which BPA may be a triggering compound to autoimmunity have been described, including its impact on hyperprolactinemia, estrogenic immune signaling, cytokine expression, and activation of macrophages, cytochrome P450 enzyme disruption, molecular mimicry to triiodothyronine, and immunoglobulin pathophysiology with increased production of IgA and IgG2a [79].

This disruption of the thyroid hormones in early life may be associated with neurobehavioral pathology later in life, especially in boys [54,55]. Data from observational studies indicate an association between both prenatal and childhood exposure to BPA and adverse behavioral outcomes in children with higher levels of anxiety, depression, and hyperactivity [83]. In vitro data suggest that BPA inhibits the TR-mediated differentiation of oligodendrocyte precursor cells [84] and perinatal exposure to low concentration of BPA inhibits synaptogenesis and affects synaptic structural modification after birth [85]. Furthermore, in Xenopus laevis brain, BPA interfered with thyroid hormone signaling and affected TH-dependent brain development [86]. Finally, the gender-specific associations between phenol exposures and children’s behaviors may be partly attributed to the fact that maternal phenols exposure may disrupt the development of sexually dimorphic brain structures of the fetus [87].

In summary, the presented studies show that early-life exposure to BPA during the fetal and perinatal period and in childhood can program molecular changes that can manifest in adulthood and pass on to subsequent generations [88]. Fetuses are extremely susceptible to environmental stress and disruptors due to their innate immaturity, while the reported effects of BPA on neurobehavioral development may be partly due to disruption of thyroid function. Maintaining normal thyroid function during the perinatal period, infancy, and childhood is extremely important for ensuring normal mental development and neurobehavior in life [89]. The present study has a number of limitations. First, due to its design, we are unable to make any conclusions regarding causation in the associations, particularly given methodological variations in the presented studies, despite the effort for this variation to be minimized. This is further hampered by the fact that BPA affects thyroid function via various physiological mechanisms, interacting in a complex and intricate manner with the molecular pathways involved. Finally, it should be noted that BPA has a relatively short half-life of 6 h in humans, as it is glucuronidated in the liver and excreted in urine, so a single spot urine sample may not be a reliable measurement [14,90]. The main strengths of our study rely in its methodology, which strictly follows PRISMA guidelines, and its novelty, as to our knowledge, this is the first systematic review summarizing the possible effects of BPA on thyroid function of children.

In conclusion, the above data suggest a negative association of BPA with TSH concentrations in children along with a gender-specific manner of action that may affect proper neurodevelopment. The presented potential impact of BPA in the developing thyroid gland of children, particularly in late gestation, reinforces the advice to limit use of BPA-contaminated products such as plastic baby bottles. Further prospectively designed studies are needed to better elucidate the association between endocrine disruptors such as BPA and the mechanisms that perturb thyroid function and organogenesis.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu14010168/s1, PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist.

Author Contributions: Conceptualization, D.K.; methodology, investigation and resources D.K. and G.P.; writing—original draft preparation, D.K. and G.P.; writing—review and editing E.C., G.P., D.K. and A.V.; supervision, E.C. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Diamanti-Kandarakis, E.; Bourguignon, J.-P.; Giudice, L.C.; Hauser, R.; Prins, G.S.; Soto, A.M.; Zoeller, R.T.; Gore, A.C. Endocrine-disrupting chemicals: An Endocrine Society scientific statement. *Endocr. Rev.* 2009, 30, 293–342. [CrossRef]

2. Solecki, R.; Kortenkamp, A.; Bergman, Å.; Chahoud, I.; Degen, G.H.; Dietrich, D.; Greim, H.; Håkansson, H.; Hass, U.; Husoy, T.; et al. Scientific principles for the identification of endocrine-disrupting chemicals: A consensus statement. *Arch. Toxicol.* 2017, 91, 1001–1006. [CrossRef] [PubMed]

3. Kang, J.-H.; Kondo, F.; Katayama, Y. Human exposure to bisphenol A. *Toxicology* 2006, 226, 79–89. [CrossRef]

4. Ali, M.; Jaghbir, M.; Salam, M.; Al-Kadamany, G.; Damsees, R.; Al-Rawashdeh, N. Testing baby bottles for the presence of residual and migrated bisphenol A. *Environ. Monit. Assess.* 2018, 191, 7. [CrossRef] [PubMed]

5. Michalowicz, J. Bisphenol A-sources, toxicity and biotransformation. *Environ. Toxicol. Pharmacol.* 2014, 37, 738–758. [CrossRef]

6. Frankowski, R.; Zgola-Grezskowiak, A.; Grzeszkoziak, T.; Söjka, K. The presence of bisphenol A in the thermal paper in the face of changing European regulations—A comparative global research. *Environ. Pollut.* 2020, 265, 114879. [CrossRef] [PubMed]

7. Rudel, R.A.; Brody, J.G.; Spengler, J.D.; Vallarino, J.; Geno, P.W.; Sun, G.; Yau, A. Identification of selected hormonally active agents and animal mammary carcinogens in commercial and residential air and dust samples. *J. Air Waste Manag. Assoc.* 2001, 51, 499–513. [CrossRef]

8. Wang, B.; Wang, H.; Zhou, W.; He, Y.; Zhou, Y.; Chen, Y.; Jiang, Q. Exposure to bisphenol A among school children in eastern China: A multicenter cross-sectional study. *J. Expo. Sci. Environ. Epidemiol.* 2014, 24, 657–664. [CrossRef] [PubMed]

9. Calafat, A.M.; Ye, X.; Wong, L.Y.; Reidy, J.A.; Needham, L.L. Exposure of the U.S. Population to Bisphenol A and 4-tertiary-Octylphenol: 2003–2004. *Environ. Health Perspect.* 2008, 116, 39–44. [CrossRef] [PubMed]

10. Manzan-Martins, C.; Paulesu, L. Impact of bisphenol A (BPA) on cells and tissues at the human materno-fetal interface. *Tissue Cell* 2021, 73, 101662. [CrossRef] [PubMed]

11. Braun, J.M.; Kalkbrenner, A.E.; Calafat, A.M.; Yolton, K.; Ye, X.; Dietrich, K.N.; Lanphear, B.P. Impact of Early-Life Bisphenol A Exposure on Behavior and Executive Function in Children. *Pediatrics* 2011, 128, 873–882. [CrossRef] [PubMed]

12. Trasande, L.; Attina, T.M.; Blustein, J. Association between Urinary Bisphenol A Concentration and Obesity Prevalence in Children and Adolescents. *JAMA* 2012, 308, 1113–1121. [CrossRef] [PubMed]

13. Pergialiotis, V.; Kotrogiani, P.; Christopoulos-Timogiannakis, E.; Koutaki, D.; Daskalakis, G.; Papantoniou, N. Bisphenol A and adverse pregnancy outcomes: A systematic review of the literature. *J. Matern. Fetal Neonatal Med.* 2018, 31, 3320–3327. [CrossRef] [PubMed]

14. Rochester, J.R. Bisphenol A and human health: A review of the literature. *Reprod. Toxicol.* 2013, 42, 132–155. [CrossRef]

15. Wetherill, Y.B.; Akingbemi, B.T.; Kanno, J.; McLachlan, J.A.; Nadal, A.; Sonnenschein, C.; Watson, C.S.; Zoeller, R.T.; Belcher, S.M. In vitro molecular mechanisms of bisphenol A action. *Reprod. Toxicol.* 2007, 101, 59–67. [CrossRef] [PubMed]

16. MacKay, H.; Abizaid, A. A plurality of molecular targets: The receptor ecosystem for bisphenol-A (BPA). *Horm. Behav.* 2018, 101, 59–67. [CrossRef] [PubMed]

17. Cimmino, I.; Fiori, F.; Perruolo, G.; Miele, C.; Beguinot, F.; Formisano, P. Potential Mechanisms of Bisphenol A (BPA) Contributing to Human Disease. *Int. J. Mol. Sci.* 2020, 21, 5761. [CrossRef]

18. Pennie, W.D.; Aldridge, T.C.; Brooks, A.N. Differential activation by xenoestrogens of ER alpha and ER beta when linked to androgen receptor. *Toxicol. Sci.* 2003, 75, 40–46. [CrossRef]

19. Takayanagi, S.; Tokunaga, T.; Liu, X.; Okada, H.; Matsushima, A.; Shimohigashi, Y. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. *Toxicol. Lett.* 2006, 167, 95–105. [CrossRef] [PubMed]

20. Kuiper, G.G.; Lemmen, J.G.; Carlsson, B.O.; Corton, J.C.; Safe, S.H.; Van Der Saag, P.T.; Van Der Burgh, B.; Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 1998, 139, 4252–4263. [CrossRef]

21. Lee, H.J.; Chattopadhyay, S.; Gong, E.-Y.; Ahn, R.S.; Lee, K. Antiandrogenic effects of bisphenol A and nonylphenol on the function of androgen receptor. *Toxicol. Sci.* 2003, 75, 40–46. [CrossRef]

22. Richter, C.A.; Taylor, J.A.; Ruhlen, R.L.; Welshons, W.V.; vom Saal, F.S. Estradiol and Bisphenol A Stimulate Androgen Receptor and Estrogen Receptor Gene Expression in Fetal Mouse Prostate Mesenchyme Cells. *Environ. Health Perspect.* 2007, 115, 902–908. [CrossRef]

23. Prasanth, G.K.; Divya, L.M.; Sadasivan, C. Bisphenol-A can bind to human glucocorticoid receptor as an agonist: An in silico study. *J. Appl. Toxicol.* 2010, 30, 769–774. [CrossRef]

24. Atlas, E.; Pope, L.; Wade, M.G.; Kawata, A.; Boudreau, A.; Boucher, J.G. Bisphenol A increases αP2 expression in 3T3L1 by enhancing the transcriptional activity of nuclear receptors at the promoter. *Adipocyte* 2014, 3, 170–179. [CrossRef] [PubMed]
25. Biasiotto, G.; Zanella, I.; Masserotti, A.; Pedrazzani, R.; Papa, M.; Caimi, L.; Di Lorenzo, D. Municipal wastewater affects adipose deposition in male mice and increases 3T3-L1 cell differentiation. *Toxicol. Appl. Pharmacol.* 2016, 297, 32–40. [CrossRef] [PubMed]

26. Singleton, D.W.; Feng, Y.; Yang, J.; Puga, A.; Lee, A.V.; Khan, S.A. Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells. *Environ. Res.* 2006, 100, 86–92. [CrossRef] [PubMed]

27. Klinge, C.M. Estrogen Regulation of MicroRNA Expression. *Curr. Genom.* 2009, 10, 169–183. [CrossRef]

28. Doherty, L.F.; Bromer, J.G.; Zhou, Y.; Aldad, T.S.; Taylor, H.S. In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: An epigenetic mechanism linking endocrine disruptors to breast cancer. *Horm. Cancer* 2010, 1, 146–155. [CrossRef]

29. Bromer, J.G.; Zhou, Y.; Taylor, M.B.; Doherty, L.; Taylor, H.S. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB J.* 2010, 24, 2273–2280. [CrossRef]

30. Moriyama, K.; Tagami, T.; Akamizu, T.; Usui, T.; Saji, M.; Kanamoto, N.; Hataya, Y.; Shimatsu, A.; Kuzuya, H.; Nakao, K. Thyroid hormone action is disrupted by bisphenol A as an antagonist. *J. Clin. Endocrinol. Metab.* 2002, 87, 5185–5190. [CrossRef]

31. Zoeller, R.T. Environmental chemicals as thyroid hormone analogues: New studies indicate that thyroid hormone receptors are targets of industrial chemicals? *Mol. Cell. Endocrinol.* 2005, 242, 10–15. [CrossRef] [PubMed]

32. Heimeier, R.A.; Das, B.; Buchholz, D.R.; Shi, Y.-B. The xenoestrogen bisphenol A inhibits postembryonic vertebrate development by antagonizing gene expression of thyroid hormone. *Endocrinology* 2009, 150, 2964–2973. [CrossRef] [PubMed]

33. Sun, H.; Shen, O.-X.; Wang, X.-R.; Zhou, L.; Zhen, S.-Q.; Chen, X.-D. Anti-thyroid hormone activity of bisphenol A, tetrabromo-bisphenol A and tetrachlorobisphenol A in an improved reporter gene assay. *Toxicol. Vitro* 2009, 23, 950–954. [CrossRef]

34. Kudo, Y.; Yamauchi, K.; Fukazawa, H.; Terao, Y. In vitro and in vivo analysis of the thyroid system-disrupting activities of brominated phenolic and phenol compounds in Xenopus laevis. *Toxicol. Sci.* 2006, 92, 87–95. [CrossRef]

35. Terasaki, M.; Kosaka, K.; Kunikane, S.; Makino, M.; Shiraishi, F. Assessment of thyroid hormone activity of halogenated bisphenol A using a yeast two-hybrid assay. *Chemosphere* 2011, 84, 1527–1530. [CrossRef]

36. Sheng, Z.G.; Tang, Y.; Liu, Y.X.; Yuan, Y.; Zhao, B.Q.; Chao, X.J.; Zhu, B.Z. Low concentrations of bisphenol a suppress thyroid hormone receptor transcription through a nongenomic mechanism. *Toxicol. Appl. Pharmacol.* 2012, 259, 133–142. [CrossRef] [PubMed]

37. Cao, J.; Guo, L.-H.; Wan, B.; Wei, Y. In vitro fluorescence displacement investigation of thyroxine transport disruption by bisphenol A. *J. Environ. Sci. China* 2011, 23, 315–321. [CrossRef]

38. Yang, J.; Chan, K.M. Evaluation of the toxic effects of brominated compounds (BDE-47, 99, 209, TBBPA) and bisphenol A (BPA) using a zebrafish liver cell line, ZFL. *Aquat. Toxicol.* 2015, 159, 138–147. [CrossRef] [PubMed]

39. Wu, Y.; Beland, F.A.; Fang, J.-L. Effect of triclosan, triclocarban, 2,2′,4,4′-tetrabromodiphenyl ether, and bisphenol A on the iodide uptake, thyroid peroxidase activity, and expression of genes involved in thyroid hormone synthesis. *Toxicol. Vitro* 2016, 32, 310–319. [CrossRef] [PubMed]

40. Gentilcore, D.; Porreca, I.; Rizzo, F.; Ganbaatar, E.; Carchia, E.; Mallardo, M.; De Felice, M.; Ambrosino, C. Bisphenol A interferes with thyroid specific gene expression. *Toxicology* 2013, 304, 21–31. [CrossRef] [PubMed]

41. Lee, S.; Kim, C.; Youn, H.; Choi, K. Thyroid hormone disrupting potentials of bisphenol A and its analogues— in vitro comparison study employing rat pituitary (GH3) and thyroid follicular (FRTL-5) cells. *Toxicol. Appl. Pharmacol.* 2015, 242, 89–95. [CrossRef] [PubMed]

42. Meeker, J.D.; Ferguson, K.K. Relationship between Urinary Phthalate and Bisphenol A Concentrations and Serum Thyroid hormone receptor transcription through a nongenomic mechanism. *Environ. Health Perspect.* 2011, 119, 1396–1402. [CrossRef]

43. Battistuzzo, A.; Ribeiro, M.O. Clinical and subclinical maternal hypothyroidism and their effects on neurodevelopment, behavior and cognition. *Arch. Endocrinol. Metab.* 2020, 64, 89–95. [CrossRef]

44. Balakrishnan, B.; Henare, K.; Thorstensen, E.B.; Ponnampalam, A.P.; Mitchell, M.D. Transfer of bisphenol A across the human placenta. *Am. J. Obstet. Gynecol.* 2010, 202, 393.e1–393.e7. [CrossRef]

45. Pop, V.J.; Brouwers, E.P.; Vader, H.L.; Vulsma, T.; van Baar, A.L.; de Vlijder, J.J. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: A 3-year follow-up study. *Clin. Endocrinol.* 2003, 59, 282–288. [CrossRef]

46. Pop, V.J.; Mestre, J.L.; Santamaria, A.; Paolozzi, I.; Franco, A.; Graells, M.; Gonzalez-Torga, A.; de Escobar, G.M. Delayed neurobehavioural development in children born to pregnant women with mild hypothyroxinaemia during the first month of gestation: The importance of early iodine supplementation. *Thyroid* 2009, 19, 511–519. [CrossRef]

47. Heindel, J.J.; Vandenberg, L.N. Developmental Origins of Health and Disease: A Paradigm for Understanding Disease Etiology and Prevention. *Curr. Opin. Pediatr.* 2015, 27, 248–253. [CrossRef]

48. Wolstenholme, J.T.; Edwards, M.; Shetty, S.R.; Gatewood, J.D.; Taylor, J.A.; Rissman, E.F.; Connelly, J.J. Gestational exposure to bisphenol a produces transgenerational changes in behaviors and gene expression. *Endocrinology* 2012, 153, 3828–3838. [CrossRef]

49. Manikkam, M.; Tracey, R.; Guerrero-Bosagna, C.; Skinner, M.K. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. *PLoS ONE* 2013, 8, e55387. [CrossRef]

50. Shamseer, L.; Moher, D.; Clarke, M.; Gherzi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. *BMJ* 2015, 350, g7647. [CrossRef]
51. Chevrier, J.; Gunier, R.B.; Bradman, A.; Holland, N.T.; Calafat, A.M.; Eskenazi, B.; Harley, K.G. Maternal urinary bisphenol A during pregnancy and maternal and neonatal thyroid function in the CHAMACOS study. *Environ. Health Perspect.* **2013**, *121*, 138–144. [CrossRef] [PubMed]

52. Romano, M.E.; Webster, G.M.; Vuong, A.M.; Zoeller, R.T.; Chen, A.; Hoofnagle, A.N.; Calafat, A.M.; Karagas, M.R.; Yolton, K.; Lanphear, B.P.; et al. Gestational urinary bisphenol A and maternal and newborn thyroid hormone concentrations: The HOME Study. *Environ. Res.* **2015**, *138*, 453–460. [CrossRef] [PubMed]

53. Brucker-Davis, F.; Ferrari, P.; Boda-Buccino, M.; Wagner-Mahler, K.; Pacini, P.; Gal, J.; Azuar, P.; Fenichel, P. Cord blood thyroid tests in boys born with and without cryptorchidism: Correlations with birth parameters and in utero xenobiotics exposure. *Thyroid* **2011**, *21*, 1133–1141. [CrossRef] [PubMed]

54. Li, F.; Yang, F.; Li, D.K.; Tian, Y.; Miao, M.; Zhang, Y.; Ji, H.; Yuan, W.; Liang, H. Prenatal bisphenol A exposure, fetal thyroid hormones and neurobehavioral development in children at 2 and 4 years: A prospective cohort study. *Sci. Total Environ.* **2020**, *722*, 137887. [CrossRef]

55. Guo, J.; Wu, C.; Zhang, J.; Li, W.; Lv, S.; Lu, D.; Qi, X.; Feng, C.; Liang, W.; Chang, X.; et al. Maternal and childhood urinary phenol concentrations, neonatal thyroid function, and metabolic diseases at 10 years of age: The SMBCS study. *Sci. Total Environ.* **2020**, *743*, 140678. [CrossRef] [PubMed]

56. Minatoya, M.; Sasaki, S.; Araki, A.; Miyashita, C.; Itoh, S.; Yamamoto, J.; Matsumura, T.; Mitsui, T.; Moriya, K.; Cho, K.; et al. Cord Blood Bisphenol A Levels and Reproductive and Thyroid Hormone Levels of Neonates: The Hokkaido Study on Environment and Children’s Health. *Epidemiology* **2017**, *28*, S3–S9. [CrossRef] [PubMed]

57. Wang, X.; Tang, N.; Nakayama, S.F.; Fan, P.; Liu, Z.; Zhang, J.; Ouyang, F. Maternal urinary bisphenol A concentration and thyroid hormone levels of Chinese mothers and newborns by maternal body mass index. *Environ. Sci. Pollut. Res. Int.* **2020**, *27*, 10939–10949. [CrossRef] [PubMed]

58. Sanlidag, B.; Dalkan, C.; Yetkin, O.; Bahçeçiler, N.N. Evaluation of Dose Dependent Maternal Exposure to Bisphenol A on Thyroid Functions in Newborns. *J. Clin. Med.* **2018**, *7*, 1. [CrossRef]

59. Jang, Y.; Choi, Y.J.; Lim, Y.H.; Lee, K.S.; Kim, B.N.; Shin, C.H.; Lee, Y.A.; Kim, J.I.; Hong, Y.C. Associations Between Thyroid Hormone Levels and Urinary Bisphenol A, and S in 6-year-old Children in Korea. *J. Prev. Med. Public Health* **2021**, *54*, 37–45. [CrossRef] [PubMed]

60. Derakhshan, A.; Philips, E.M.; Ghassabian, A.; Santos, S.; Asimakopoulous, A.G.; Kannan, K.; Kortenkamp, A.; Jaddoe, V.W.; Trasande, L.; Peeters, R.P.; et al. Association of urinary bisphenols during pregnancy with maternal, cord blood and childhood thyroid function. *Environ. Int.* **2021**, *146*, 106160. [CrossRef] [PubMed]

61. Wang, N.; Zhou, Y.; Fu, C.; Wang, H.; Huang, F.; Wang, B.; Su, M.; Jiang, F.; Fang, H.; Zhao, Q.; et al. Influence of Bisphenol A on Thyroid Volume and Structure Independent of Iodine in School Children. *PLoS ONE* **2015**, *10*, e0141248. [CrossRef]

62. Sur, U.; Erkekoglu, P.; Bulus, A.D.; Andiran, N.; Kocer-Gumusel, B. Oxidative stress markers, trace elements, and endocrine disrupting chemicals in children with Hashimoto’s thyroiditis. *Toxicol. Mech. Methods*. **2019**, *29*, 633–643. [CrossRef]

63. Vandenberg, L.N.; Hauser, R.; Marcus, M.; Olea, N.; Welschons, W.V. Human exposure to bisphenol A (BPA). *Reprod. Toxicol.* **2007**, *24*, 139–177. [CrossRef] [PubMed]

64. Yuan, N.; Wang, L.; Zhang, X.; Li, W. Bisphenol A and thyroid hormones: Bibliometric analysis of scientific publications. *Medicine* **2020**, *99*, e23067. [CrossRef]

65. Wang, T.; Lu, J.; Xu, M.; Xu, Y.; Li, M.; Liu, Y.; Tian, X.; Chen, Y.; Dai, M.; Wang, W.; et al. Urinary bisphenol a concentration and thyroid function in Chinese adults. *Environ. Int.* **2013**, *49*, 295–302. [CrossRef] [PubMed]

66. Aung, M.T.; Johns, L.E.; Ferguson, K.K.; Mukherjee, B.; McLelrath, T.F.; Meeker, J.D. Thyroid hormone parameters during pregnancy in relation to urinary bisphenol A concentrations: A repeated measures study. *Environ. Int.* **2017**, *104*, 34–40. [CrossRef]

67. Kaneko, M.; Okada, R.; Yamamoto, K.; Nakamura, M.; Mosconi, G.; Polzonetti-Magni, A.M.; Kikuyama, S. Bisphenol A acts in vitro, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. *Am. J. Dis. Child* **2005**, *159*, 149–155. [CrossRef] [PubMed]

68. Vyas, A.K.; Veiga-Lopez, A.; Ye, W.; Abi Salloum, B.; Abbott, D.H.; Yang, S.; Liao, C.; Kannan, K.; Padmanabhan, V. Developmental programming: Sex-specific programming of growth upon prenatal bisphenol A exposure. *J. Appl. Toxicol.* **2019**, *39*, 1516–1531. [CrossRef]
74. Ikezuki, Y.; Tsutsumi, O.; Takai, Y.; Kamei, Y.; Taketani, Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. *Hum. Reprod.* **2002**, *17*, 2839–2841. [CrossRef]

75. Pop, V.J.; Kuijpers, J.L.; van Baar, A.L.; Verkerk, G.; van Son, M.M.; de Vijlder, J.J.; Vulsma, T.; Wiersinga, W.M.; Drexhage, H.A.; Vader, H.L. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin. Endocrinol.* **1999**, *50*, 149–155. [CrossRef]

76. Coughtrie, M.W.; Burchell, B.; Leakey, J.E.; Hume, R. The inadequacy of perinatal glucuronidation: Immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. *Mol. Pharmacol.* **1988**, *34*, 729–735.

77. Eng, L.; Lam, L. Thyroid Function during the Fetal and Neonatal Periods. *NeoReviews* **2020**, *21*, e30–e36. [CrossRef]

78. Shapira, Y.; Agmon-Levin, N.; Shoenfeld, Y. Defining and analyzing geoepidemiology and human autoimmunity. *J. Autoimmun.* **2010**, *34*, J168–J177. [CrossRef]

79. Kharrazian, D. The Potential Roles of Bisphenol A (BPA) Pathogenesis in Autoimmunity. *Autoimmune Dis.* **2014**, *2014*, 743616. [CrossRef]

80. Midoro-Horiuti, T.; Tiwari, R.; Watson, C.S.; Goldblum, R.M. Maternal Bisphenol A Exposure Promotes the Development of Experimental Asthma in Mouse Pups. *Environ. Health Perspect.* **2010**, *118*, 273–277. [CrossRef] [PubMed]

81. Hanley, P.; Lord, K.; Bauer, A.J. Thyroid Disorders in Children and Adolescents: A Review. *JAMA Pediatr.* **2016**, *170*, 1008–1019. [CrossRef] [PubMed]

82. Chailurkit, L.; Aekplakorn, W.; Ongphiphadhanakul, B. The Association of Serum Bisphenol A with Thyroid Autoimmunity. *Int. J. Environ. Res. Public Health* **2016**, *13*, 1153. [CrossRef] [PubMed]

83. Seiwa, C.; Nakahara, J.; Komiyama, T.; Katsu, Y.; Iguchi, T.; Asou, H. Bisphenol A exerts thyroid-hormone-like effects on mouse oligodendrocyte precursor cells. *Neuroendocrinology* **2004**, *80*, 21–30. [CrossRef] [PubMed]

84. Xu, X.; Xie, L.; Hong, X.; Ruan, Q.; Lu, H.; Zhang, Q.; Zhang, G.; Liu, X. Perinatal exposure to bisphenol-A inhibits synaptogenesis and affects the synaptic morphological development in offspring male mice. *Chemosphere* **2013**, *91*, 1073–1081. [CrossRef]

85. Niu, Y.; Zhu, M.; Dong, M.; Li, J.; Li, Y.; Xiong, Y.; Liu, P.; Qin, Z. Bisphenols disrupt thyroid hormone (TH) signaling in the brain and affect TH-dependent brain development in *Xenopus laevis*. *Aquat. Toxicol.* **2021**, *237*, 105902. [CrossRef]

86. Grohs, M.N.; Reynolds, J.E.; Liu, J.; Martin, J.W.; Pollock, T.; Lebel, C.; Dewey, D. Prenatal maternal and childhood bisphenol a exposure and brain structure and behavior of young children. *Environ. Health* **2019**, *18*, 85. [CrossRef]

87. Walker, D.M.; Gore, A.C. Transgenerational neuroendocrine disruption of reproduction. *Nat. Rev. Endocrinol.* **2011**, *7*, 197–207. [CrossRef]

88. Levie, D.; Korevaar, T.I.; Bath, S.C.; Dalmau-Bueno, A.; Murcia, M.; Espada, M.; Dineva, M.; Ibarluzea, J.M.; Sunyer, J.; Tiemeier, H.; et al. Thyroid Function in Early Pregnancy, Child IQ, and Autistic Traits: A Meta-Analysis of Individual Participant Data. *J. Clin. Endocrinol. Metab.* **2018**, *103*, 2967–2979. [CrossRef]

89. Pottinger, L.H.; Domoradzki, J.Y.; Markham, D.A.; Hansen, S.C.; Cagen, S.Z.; Waechter, J.M. The relative bioavailability and metabolism of bisphenol A in rats is dependent upon the route of administration. *Toxicol. Sci.* **2000**, *54*, 3–18. [CrossRef]